Consensus of expert through Indian perspective on the fixed-dose combination dapagliflozin and linagliptin combination in type 2 diabetes mellitus: CONSEPDT study
DOI:
https://doi.org/10.18203/2320-6012.ijrms20254400Keywords:
Type 2 diabetes mellitus, Dapagliflozin-linagliptin fixed-dose combination, Cardiorenal protection, Expert consensus (India)Abstract
Effective management of type 2 diabetes mellitus (T2DM) increasingly demands a shift from a glucose-centric model to a comorbidity-centric approach, particularly in populations with high cardio-renal risk profiles. The fixed-dose combination (FDC) of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), and linagliptin, a dipeptidyl peptidase-4 inhibitor (DPP4i), presents a synergistic, safe, and effective treatment option for patients with complex comorbidities. This combination not only improves glycemic control but also offers pleiotropic benefits, such as weight neutrality and reduced risk of hypoglycemia. Despite robust clinical evidence supporting its efficacy and safety, the absence of standardized, region-specific guidelines has led to inconsistent adoption in clinical practice across India. A consensus tailored to Indian clinical settings is necessary to ensure rational, evidence-based, and uniform use of this FDC. Such a framework will assist healthcare providers in making informed decisions, improving adherence, minimizing complications, and ultimately enhancing patient outcomes. The consensus aims to harmonize diabetes management by incorporating global evidence into local clinical practice.
Metrics
References
Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting | Diabetes Therapy. Available at: https://link.springer.com/article/10.1007/s13300-022-01219-x. Accessed on 15 March 2025.
Jain A, Vispute A, Dange A, Naskar A, Mondal A, Vivekanand B, et al. A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin. Diabetes Ther. 2024;15(1):215-27. DOI: https://doi.org/10.1007/s13300-023-01504-3
Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm-2023 Update. Endocr Pract. 2023;29(5):305-40. DOI: https://doi.org/10.1016/j.eprac.2023.02.001
Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Ther. 2022;13(5):1097-114. DOI: https://doi.org/10.1007/s13300-022-01219-x
IDF Diabetes Atlas 2025. Diabetes Atlas. Available at: https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/. Accessed on 27 March 2025.
Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-8. DOI: https://doi.org/10.4103/ijo.IJO_1627_21
Khunti K, Aroda VR. Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes. Diabetes Care. 2022;45(4):766-8. DOI: https://doi.org/10.2337/dci21-0064
Hong JH, Kim MJ, Min KW, Won JC, Kim TN, Lee BW, et al. Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study. Diabetes Obes Metab. 2025;27(1):81-91.
Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025 | Diabetes Care | American Diabetes Association. Available at: https://diabetesjournals.org/care/article/48/Supplement_1/S181/157569/9-Pharmacologic-Approaches-to-Glycemic-Treatment. Accessed on 06 May 2025.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2023;44(37):3627-39. DOI: https://doi.org/10.1093/eurheartj/ehad195
Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S, et al. RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. Int J Diabetes Dev Ctries. 2020;40(S1):1-122. DOI: https://doi.org/10.1007/s13410-020-00819-2
Dharmalingam M, Kumar Sharma S, Prakash V, Maiti A, Kumar R, Murthy LSS, et al. Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin. Cureus. 2024;16(4):e58115. DOI: https://doi.org/10.7759/cureus.58115
Ahmad J, Ghosh S, Kumthekar PP, Upadhyay MR, Sonawane KR, Khalse M, et al. 932-P: Clinical Efficacy, Safety, and Tolerability of Single-Pill Combination of Dapagliflozin and Linagliptin in Uncontrolled Indian Type 2 Diabetes Mellitus Patients-A Randomized Double-Blind Study. Diabetes. 2024;73(1):932-P. DOI: https://doi.org/10.2337/db24-932-P
Kumthekar P, Upadhyay MR, Tamma RR, Kranti V, Bhattacharya R, Sharma PK, et al. Fixed-dose Combination of Dapagliflozin and Linagliptin in Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Randomized Double-blind Multicenter Trial. J Diabetol. 2025;16(1):50. DOI: https://doi.org/10.4103/jod.jod_169_24
American Diabetes Association. Standards of Care in Diabetes-2025.Diabetes Care. 2025;48(1). DOI: https://doi.org/10.2337/dc25-SDIS
Dal Canto E, Ceriello A, Rydén L, Ferrini M, Hansen TB, Schnell O, et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2):25-32. DOI: https://doi.org/10.1177/2047487319878371
Hong JH, Kim MJ, Min KW, Won JC, Kim TN, Lee B, et al. Efficacy and safety of a fixed‐dose combination of dapagliflozin and linagliptin (AJU‐A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled phase III study. Diabetes Obes Metab. 2025;27(1):81-91. DOI: https://doi.org/10.1111/dom.15985
RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022. Int J Diabetes Dev Ctries. 2022;42(S1):1-143. DOI: https://doi.org/10.1007/s13410-022-01129-5
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. DOI: https://doi.org/10.1056/NEJMoa2024816
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA. 2019;322(12):1-12. DOI: https://doi.org/10.1001/jama.2019.13772
Nesbitt H. American Society of Nephrology | Kidney Week-Abstract Details. 2024. Available at: https://www.asn-online.org/education/kidneyweek/2024/program-abstract.aspx?controlId=4176408. Accessed on 06 May 2025.
Cho YK, Kang YM, Lee SE, Lee J, Park JY, Lee WJ, et al. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2018;44(5):393-401. DOI: https://doi.org/10.1016/j.diabet.2018.01.011
Zhu Y, Zhang J li, Yan X jiao, Sun L, Ji Y, Wang F fang. Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2022;21:186. DOI: https://doi.org/10.1186/s12933-022-01627-0
Downloads
Published
How to Cite
Issue
Section
